Through ELISA, IMP2 has been shown to trigger an autoimmune response in breast cancer, as evidenced by the presence of autoantibodies [99], suggesting the potential of screening for IMP2 as a biomarker for breast cancer. This evidence concerns the gene IGF2BP2 and breast carcinoma.